Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026. The meeting, held in Milan, Italy, included the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. The motions for the extraordinary part of the meeting were not put to vote because the required quorum was not reached.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected board members. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long-standing service, for their support of the company.
Newron Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system diseases. The company's lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia. Evenamide is currently in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results to date show significant improvements across key efficacy measures that increase over time, along with a favorable safety profile, which is uncommon for available antipsychotic medications.
Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. The company's first marketed product, Xadago®/safinamide, has received marketing authorization for the treatment of Parkinson's disease in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron's partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories.
The implications of the board elections include fresh perspectives and independent oversight, which are crucial as Newron advances its pivotal Phase III program for evenamide. The successful development of evenamide could address a significant unmet medical need for patients with TRS, who currently have limited treatment options. The company's progress also highlights the ongoing innovation in neuroscience-based therapies and the potential for improved outcomes in schizophrenia and Parkinson's disease.
For more information about Newron and its pipeline, visit www.newron.com. The original press release is available at www.newmediawire.com.
